A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Name: A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Published: 2022
License: Public Domain

Amgen · 2022

ClinicalTrials.gov · Datasets · License: Public Domain · 2022

Open Source ↗

smallcelllungcancer

non-small cell lung cancer, kras p.g12c, sotorasib, amg 510, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment

Related documents